• Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=11799138).
  

PubMed=8725545; DOI=10.3109/00016489609137854
Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.
Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma.
Acta Oto-Laryngol. 116:341-344(1996)

PubMed=11799138; DOI=10.1177/002215540205000207
Eicheler W., Zips D., Dorfler A., Grenman R., Baumann M.
Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection.
J. Histochem. Cytochem. 50:197-204(2002)

PubMed=16331601; DOI=10.1002/ijc.21514
Muller A., Sonkoly E., Eulert C., Gerber P.A., Kubitza R., Schirlau K., Franken-Kunkel P., Poremba C., Snyderman C.H., Klotz L.-O., Ruzicka T., Bier H., Zlotnik A., Whiteside T.L., Homey B., Hoffmann T.K.
Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy.
Int. J. Cancer 118:2147-2157(2006)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=18487078; DOI=10.1016/j.oraloncology.2008.02.006
Hoffmann T.K., Sonkoly E., Hauser U., van Lierop A., Whiteside T.L., Klussmann J.P., Hafner D., Schuler P.J., Friebe-Hoffmann U., Scheckenbach K., Erjala K., Grenman R., Schipper J., Bier H., Balz V.
Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.
Oral Oncol. 44:1100-1109(2008)

DOI=10.1158/1538-7445.AM2020-507
Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J., Koritzinsky M., Wouters B.G.
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)